Go Pro
→ A Dark Day Is Coming to America (From TradeSmith) (Ad)tc pixel Free CSBR Stock Alerts

Champions Oncology (CSBR) Financials

Champions Oncology logo
$5.07 -0.01 (-0.20%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$5.04 -0.03 (-0.59%)
As of 08/14/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Champions Oncology

Annual Income Statements for Champions Oncology

This table shows Champions Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025 4/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -10 -6.88 -1.48 0.13 -2.09 0.36 0.55 -5.34 -7.28 4.70 -1.18
Consolidated Net Income / (Loss)		 -10 -6.88 -1.48 0.13 -2.09 0.36 0.55 -5.34 -7.28 4.70 -1.18
Net Income / (Loss) Continuing Operations		 -10 -6.88 -1.48 0.13 -2.09 0.36 0.55 -5.34 -7.28 4.70 -1.18
Total Pre-Tax Income 		-10 -6.87 -1.44 0.23 -1.96 0.44 0.58 -5.27 -7.31 4.63 -0.93
Total Operating Income		 -10 -6.81 -1.35 0.27 -1.92 0.37 0.61 -5.26 -7.36 4.55 -1.14
Total Gross Profit		 11 15 20 27 15 20 25 24 21 29 29
Total Revenue		 11 15 20 27 32 41 49 54 50 57 59
Operating Revenue		 11 15 20 27 32 41 49 54 50 57 59
Total Cost of Revenue		 0.00 0.00 0.00 0.00 17 21 24 30 29 28 31
Operating Cost of Revenue		 - - - - 17 21 24 30 29 28 31
Total Operating Expenses		 21 22 22 27 17 19 25 30 28 24 30
Selling, General & Admin Expense		 5.17 4.96 4.07 4.68 6.61 6.51 9.12 10 11 9.34 11
Marketing Expense		 3.45 3.26 2.57 3.06 4.24 5.52 6.38 7.00 7.06 7.55 9.32
Research & Development Expense		 4.19 4.29 4.40 4.80 5.85 7.20 9.37 12 9.54 6.83 9.08
Other Special Charges / (Income)		 - - - - - - - 0.00 0.44 0.29 0.11
Total Other Income / (Expense), net		 -0.04 -0.06 -0.09 -0.04 -0.04 0.07 -0.02 -0.01 0.05 0.07 0.21
Other Income / (Expense), net		 -0.04 -0.06 -0.09 -0.04 -0.04 0.07 -0.02 -0.01 0.05 0.07 0.21
Income Tax Expense		 0.09 0.02 0.03 0.10 0.13 0.08 0.04 0.07 -0.03 -0.08 0.25
Basic Earnings per Share		 ($1.20) ($0.64) ($0.13) $0.01 ($0.18) $0.03 $0.04 ($0.39) ($0.54) $0.34 ($0.08)
Weighted Average Basic Shares Outstanding		 8.70M 10.68M 10.99M 11.34M 11.84M 13.14M 13.20M 13.54M 13.55M 13.66M 13.83M
Diluted Earnings per Share		 ($1.20) ($0.64) ($0.13) $0.01 ($0.18) $0.02 $0.04 ($0.39) ($0.54) $0.33 ($0.08)
Weighted Average Diluted Shares Outstanding		 8.70M 10.68M 10.99M 14.10M 11.84M 14.57M 14.16M 13.54M 13.55M 14.27M 13.83M
Weighted Average Basic & Diluted Shares Outstanding		 8.70M 10.68M 10.99M 11.62M 12.73T 13.42M 13.52M 13.46M 13.59M 13.78M 13.89M

Quarterly Income Statements for Champions Oncology

This table shows Champions Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025 7/31/2025 10/31/2025 1/31/2026 4/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.07 -2.53 -0.11 1.31 0.73 4.50 -1.84 -0.44 0.27 -0.28 -0.73
Consolidated Net Income / (Loss)		 -2.07 -2.53 -0.11 1.31 0.73 4.50 -1.84 -0.47 0.24 -0.28 -0.67
Net Income / (Loss) Continuing Operations		 -2.07 -2.53 -0.11 1.31 0.73 4.50 -1.84 -0.47 0.24 -0.28 -0.67
Total Pre-Tax Income 		-2.06 -2.52 -0.19 1.33 0.74 4.52 -1.97 -0.45 0.26 -0.24 -0.50
Total Operating Income		 -1.96 -2.58 -0.27 1.33 0.73 4.50 -2.01 -0.53 0.19 -0.28 -0.52
Total Gross Profit		 4.96 4.17 6.75 6.99 6.06 10 5.08 6.00 7.77 7.73 7.03
Total Revenue		 12 12 14 14 13 17 12 14 15 17 14
Operating Revenue		 12 12 14 14 13 17 12 14 15 17 14
Total Cost of Revenue		 6.62 7.85 7.25 7.07 7.43 6.62 7.27 8.00 7.26 8.83 6.81
Operating Cost of Revenue		 6.62 7.85 7.25 7.07 7.43 6.62 7.27 8.00 7.26 8.83 6.81
Total Operating Expenses		 6.91 6.75 7.02 5.66 5.33 5.92 7.09 6.53 7.59 8.00 7.55
Selling, General & Admin Expense		 2.60 2.76 2.76 2.53 1.89 2.40 2.53 2.57 2.97 2.98 2.63
Marketing Expense		 1.80 1.80 1.78 1.68 1.75 1.81 2.31 1.86 2.00 2.67 2.80
Research & Development Expense		 2.52 2.19 2.05 1.45 1.69 1.72 1.96 2.08 2.62 2.27 2.12
Other Special Charges / (Income)		 - - - 0.00 0.00 0.00 - 0.02 0.00 0.09 0.00
Total Other Income / (Expense), net		 -0.11 0.06 0.08 0.01 0.01 0.02 0.04 0.08 0.07 0.04 0.03
Other Income / (Expense), net		 -0.11 0.06 0.08 0.01 0.01 0.02 0.04 0.08 0.07 0.04 0.03
Income Tax Expense		 0.01 0.01 -0.08 0.02 0.01 0.02 -0.13 0.01 0.02 0.04 0.17
Basic Earnings per Share		 ($0.15) ($0.19) ($0.01) $0.10 $0.05 $0.33 ($0.14) ($0.03) $0.02 ($0.02) ($0.05)
Weighted Average Basic Shares Outstanding		 13.50M 13.59M 13.55M 13.59M 13.59M 13.70M 13.66M 13.79M 13.79M 13.89M 13.83M
Diluted Earnings per Share		 ($0.15) ($0.19) ($0.01) $0.09 $0.05 $0.31 ($0.12) ($0.03) $0.02 ($0.02) ($0.05)
Weighted Average Diluted Shares Outstanding		 13.50M 13.59M 13.55M 14.04M 14.02M 14.36M 14.27M 13.79M 14.46M 13.89M 13.83M
Weighted Average Basic & Diluted Shares Outstanding		 13.59M 13.59M 13.59M 13.59M 13.82M 13.83M 13.78M 13.79M 13.89M 13.89M 13.89M

Annual Cash Flow Statements for Champions Oncology

This table details how cash moves in and out of Champions Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025 4/30/2026
Net Change in Cash & Equivalents		 -6.77 0.71 -2.44 2.23 5.11 -3.66 4.32 1.11 -7.50 7.17 -4.91
Net Cash From Operating Activities		 -6.41 -2.84 -1.23 1.86 2.91 -1.68 6.50 3.97 -6.14 7.39 -4.47
Net Cash From Continuing Operating Activities		 -6.42 -2.84 -1.23 1.86 2.91 -1.68 6.50 3.97 -6.14 7.39 -4.47
Net Income / (Loss) Continuing Operations		 -10 -6.88 -1.48 0.13 -2.09 0.36 0.55 -5.34 -7.28 4.70 -1.18
Consolidated Net Income / (Loss)		 -10 -6.88 -1.48 0.13 -2.09 0.36 0.55 -5.34 -7.28 4.70 -1.18
Depreciation Expense		 0.16 0.17 0.36 0.61 0.83 1.18 1.63 2.25 1.87 1.64 1.38
Non-Cash Adjustments To Reconcile Net Income		 2.67 2.73 0.99 0.71 1.16 0.73 1.99 1.91 1.93 0.52 1.16
Changes in Operating Assets and Liabilities, net		 1.20 1.15 -1.10 0.42 3.01 -3.96 2.34 5.15 -2.65 0.52 -5.84
Net Cash From Investing Activities		 -0.32 -0.77 -1.23 -0.83 -2.22 -3.17 -2.38 -2.87 -0.84 -0.39 -0.54
Net Cash From Continuing Investing Activities		 -0.32 -0.77 -1.23 -0.83 -2.22 -3.17 -2.38 -2.87 -0.84 -0.39 -0.54
Purchase of Property, Plant & Equipment		 -0.32 -0.77 -1.23 -0.83 -2.22 -3.28 -2.38 -2.87 -0.84 -0.39 -0.56
Sale of Property, Plant & Equipment		 - 0.00 0.00 - - - - - - 0.00 0.02
Net Cash From Financing Activities		 -0.04 4.32 0.01 1.20 4.42 1.20 0.21 0.01 -0.53 0.17 0.10
Net Cash From Continuing Financing Activities		 -0.04 4.32 0.01 1.20 4.42 1.20 0.21 0.01 -0.53 0.17 0.10
Other Financing Activities, net		 - 0.00 0.04 1.47 4.42 1.20 0.21 0.09 0.11 0.17 0.10

Quarterly Cash Flow Statements for Champions Oncology

This table details how cash moves in and out of Champions Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025 7/31/2025 10/31/2025 1/31/2026 4/30/2026
Net Change in Cash & Equivalents		 0.64 -1.05 -1.85 0.27 -0.14 0.45 6.58 0.54 -1.81 -1.39 -2.26
Net Cash From Operating Activities		 0.59 -0.92 -1.82 0.31 -0.28 0.49 6.87 0.60 -1.74 -1.34 -2.00
Net Cash From Continuing Operating Activities		 0.59 -0.92 -1.82 0.31 -0.28 0.49 6.87 0.60 -1.74 -1.34 -2.00
Net Income / (Loss) Continuing Operations		 -2.07 -2.53 -0.11 1.31 0.73 4.50 -1.84 -0.47 0.24 -0.28 -0.67
Consolidated Net Income / (Loss)		 -2.07 -2.53 -0.11 1.31 0.73 4.50 -1.84 -0.47 0.24 -0.28 -0.67
Depreciation Expense		 0.48 0.48 0.46 0.45 0.40 0.40 0.39 0.36 0.36 0.34 0.32
Non-Cash Adjustments To Reconcile Net Income		 0.71 0.76 -0.11 0.48 -0.56 1.17 1.76 0.15 0.20 0.43 0.38
Changes in Operating Assets and Liabilities, net		 1.46 0.38 -2.06 -1.93 -0.85 -5.57 6.55 0.56 -2.53 -1.83 -2.03
Net Cash From Investing Activities		 -0.08 -0.09 0.00 0.00 -0.09 -0.04 -0.25 -0.05 -0.24 -0.01 -0.24
Net Cash From Continuing Investing Activities		 -0.08 -0.09 0.00 0.00 -0.09 -0.04 -0.25 -0.05 -0.24 -0.01 -0.24
Purchase of Property, Plant & Equipment		 -0.08 -0.09 0.00 0.00 -0.09 -0.04 -0.25 -0.05 -0.24 -0.04 -0.24
Sale of Property, Plant & Equipment		 - - - - - - - - - - 0.00
Net Cash From Financing Activities		 0.13 -0.03 -0.04 -0.04 0.24 - -0.03 -0.01 0.17 -0.04 -0.02
Net Cash From Continuing Financing Activities		 0.13 -0.03 -0.04 -0.04 0.24 - -0.03 -0.01 0.17 -0.04 -0.02
Other Financing Activities, net		 0.17 -0.03 -0.04 -0.04 0.24 - -0.03 -0.01 0.17 -0.04 -0.02

Annual Balance Sheets for Champions Oncology

This table presents Champions Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025 4/30/2026
Total Assets		 5.78 8.01 8.08 11 21 28 35 34 26 32 27
Total Current Assets		 4.34 5.87 5.06 7.92 13 13 20 19 14 22 19
Cash & Equivalents		 2.59 3.30 - 3.24 8.34 4.69 9.01 10 2.62 9.79 4.87
Accounts Receivable		 1.31 2.27 3.92 4.38 4.77 6.99 9.51 8.01 9.53 11 13
Prepaid Expenses		 0.44 0.30 0.29 0.31 0.39 0.96 1.14 1.33 1.50 1.37 1.17
Plant, Property, & Equipment, net		 0.62 1.22 2.08 2.55 3.99 0.00 7.13 7.19 5.72 4.38 3.53
Total Noncurrent Assets		 0.82 0.93 0.94 0.80 3.26 15 8.58 7.67 6.77 5.61 4.24
Goodwill		 0.67 0.67 0.67 0.67 0.34 0.34 0.34 0.34 0.34 0.34 0.34
Other Noncurrent Operating Assets		 0.00 0.11 0.12 0.13 2.93 15 8.25 7.33 6.44 5.28 3.91
Total Liabilities & Shareholders' Equity		 5.78 8.01 8.08 11 21 28 35 34 26 32 27
Total Liabilities		 5.54 7.61 8.08 9.03 16 20 26 30 28 29 23
Total Current Liabilities		 5.31 7.45 7.45 8.03 12 11 17 22 22 24 20
Accounts Payable		 1.90 1.85 2.15 2.81 3.14 1.89 2.87 5.33 5.80 4.25 6.90
Accrued Expenses		 0.27 0.69 0.57 1.18 2.72 2.23 2.41 2.27 2.16 2.56 2.59
Current Deferred Revenue		 3.14 4.91 4.70 4.02 5.82 6.26 11 13 12 15 8.83
Other Current Liabilities		 - - - 0.00 0.63 0.82 1.13 1.35 1.49 1.61 1.60
Total Noncurrent Liabilities		 0.23 0.16 0.62 1.00 3.35 8.96 8.80 7.94 6.49 4.72 3.00
Other Noncurrent Operating Liabilities		 0.23 0.16 0.15 0.15 3.35 8.96 8.80 7.94 6.49 4.72 3.00
Total Equity & Noncontrolling Interests		 0.24 0.40 0.00 2.24 5.10 7.43 9.10 4.64 -1.90 3.77 4.07
Total Preferred & Common Equity		 0.24 0.40 0.00 2.24 5.10 7.43 9.10 4.64 -1.90 3.77 3.94
Total Common Equity		 0.24 0.40 0.00 2.24 5.10 7.43 9.10 4.64 -1.90 3.77 3.94
Common Stock		 64 71 72 73 78 80 81 82 83 84 86
Retained Earnings		 -62 -69 -71 -71 -73 -73 -72 -77 -85 -80 -81
Treasury Stock		 -1.25 -1.25 -1.25 - - - 0.00 -0.07 -0.71 -0.71 -0.71
Noncontrolling Interest		 - - - - - - - - - 0.00 0.13

Quarterly Balance Sheets for Champions Oncology

This table presents Champions Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 7/31/2023 10/31/2023 1/31/2024 7/31/2024 10/31/2024 1/31/2025 7/31/2025 10/31/2025 1/31/2026
Total Assets		 30 28 27 25 25 31 31 30 28
Total Current Assets		 15 14 13 13 14 20 21 21 20
Cash & Equivalents		 4.87 5.51 4.47 2.89 2.75 3.20 10 8.52 7.13
Accounts Receivable		 8.95 7.72 7.90 9.03 10 16 9.47 12 12
Prepaid Expenses		 1.11 0.78 0.84 1.25 0.86 0.71 1.22 1.28 0.99
Plant, Property, & Equipment, net		 7.37 6.94 6.53 5.27 4.97 5.04 4.23 3.95 3.71
Total Noncurrent Assets		 7.61 7.34 7.06 6.48 6.19 5.89 5.30 4.88 4.56
Goodwill		 0.34 0.34 0.34 0.34 0.34 0.34 0.34 0.34 0.34
Other Noncurrent Operating Assets		 7.28 7.00 6.72 6.15 5.85 5.56 4.97 4.54 4.22
Total Liabilities & Shareholders' Equity		 30 28 27 25 25 31 31 30 28
Total Liabilities		 28 28 29 25 25 25 27 26 24
Total Current Liabilities		 20 21 22 19 19 20 23 22 21
Accounts Payable		 5.76 4.54 4.76 5.24 4.85 5.09 4.85 5.99 5.73
Accrued Expenses		 2.09 2.02 2.43 2.10 2.24 2.27 1.80 2.19 3.35
Current Deferred Revenue		 11 13 13 10 10 11 14 12 10.00
Other Current Liabilities		 1.39 1.42 1.31 1.52 1.55 1.59 1.62 1.62 1.61
Total Noncurrent Liabilities		 7.62 7.25 6.88 6.10 5.70 5.29 4.31 3.79 3.39
Other Noncurrent Operating Liabilities		 7.62 7.25 6.88 6.10 5.70 5.29 4.31 3.79 3.39
Total Equity & Noncontrolling Interests		 1.90 0.09 -2.06 -0.33 0.68 5.47 3.54 4.23 4.38
Total Preferred & Common Equity		 1.90 0.09 -2.06 -0.33 0.68 5.47 3.51 4.17 4.28
Total Common Equity		 1.90 0.09 -2.06 -0.33 0.68 5.47 3.51 4.17 4.28
Common Stock		 82 83 83 84 84 84 85 85 85
Retained Earnings		 -80 -82 -84 -83 -83 -78 -80 -80 -80
Treasury Stock		 -0.68 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71
Noncontrolling Interest		 - - - - - - 0.03 0.06 0.10

Annual Metrics And Ratios for Champions Oncology

This table displays calculated financial ratios and metrics derived from Champions Oncology's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025 4/30/2026
DEI Shares Outstanding		 8,702,237.00 10,978,352.00 11,000,847.00 11,615,272.00 11,887,649.00 13,390,172.00 13,522,441.00 13,558,650.00 13,593,767.00 13,826,904.00 13,886,826.00
DEI Adjusted Shares Outstanding		 8,702,237.00 10,978,352.00 11,000,847.00 11,615,272.00 11,887,649.00 13,390,172.00 13,522,441.00 13,558,650.00 13,593,767.00 13,826,904.00 13,886,826.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.20 -0.63 -0.13 0.01 -0.18 0.03 0.04 -0.39 -0.54 0.34 -0.08
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 37.82% 31.34% 33.72% 18.68% 27.76% 19.66% 9.69% -6.90% 13.54% 4.36%
EBITDA Growth		 -4,865.42% 34.33% 83.83% 177.29% -235.96% 242.44% 36.34% -236.70% -80.11% 215.16% -92.85%
EBIT Growth		 0.00% 33.70% 78.98% 116.01% -949.78% 122.26% 33.41% -1,003.43% -38.75% 163.30% -120.08%
NOPAT Growth		 0.00% 34.00% 80.11% 115.79% -998.80% 122.55% 88.19% -744.84% -39.95% 189.86% -117.25%
Net Income Growth		 0.00% 34.10% 78.56% 108.67% -1,735.16% 117.30% 51.38% -1,073.54% -36.38% 164.61% -124.99%
EPS Growth		 45.45% 46.67% 79.69% 107.69% -1,900.00% 111.11% 100.00% -1,075.00% -38.46% 161.11% -124.24%
Operating Cash Flow Growth		 33.46% 55.68% 56.83% 251.88% 56.02% -157.87% 486.50% -38.86% -254.51% 220.35% -160.55%
Free Cash Flow Firm Growth		 -342.43% 31.80% 7.81% 126.45% -11.02% -720.65% 156.73% -41.30% -422.98% 200.14% -198.17%
Invested Capital Growth		 -70.91% -21.95% 96.58% -845.19% -229.91% 184.52% -96.75% -6,259.55% 17.53% -33.00% 86.63%
Revenue Q/Q Growth		 310.80% 6.07% 6.32% 11.52% 3.31% 4.63% 4.94% 0.36% 1.89% -2.81% 2.56%
EBITDA Q/Q Growth		 -417.40% 2.09% 63.26% 174.43% -259.61% 1,137.40% 33.94% -259.22% 29.02% -22.67% 147.21%
EBIT Q/Q Growth		 -439.36% 2.05% 55.49% 198.30% -4,933.33% 143.88% 102.43% -71.45% 24.33% -27.72% 61.28%
NOPAT Q/Q Growth		 -336.68% 2.31% 56.99% 200.82% -31,916.67% 142.55% 176.87% -72.55% 23.41% -26.73% 56.57%
Net Income Q/Q Growth		 -765.95% 2.10% 54.84% 150.79% -1,069.27% 132.01% 150.23% -71.10% 25.21% -26.86% 49.85%
EPS Q/Q Growth		 0.00% 13.51% 53.57% 150.00% -500.00% 122.22% 0.00% -77.27% 25.00% -25.00% 46.67%
Operating Cash Flow Q/Q Growth		 18.48% 25.13% -46.48% 15.01% 374.67% -159.11% 74.60% -27.25% -22.42% 669.03% -201.78%
Free Cash Flow Firm Q/Q Growth		 -454.25% 5.53% -27.02% 920.26% 238.22% -352.44% 3,325.60% -36.91% -24.00% 362.67% -288.99%
Invested Capital Q/Q Growth		 -110.90% -90.55% 85.95% -28.83% -2,988.57% 525.80% -83.82% -19.67% 29.10% -365.24% 70.75%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 47.08% 47.74% 51.88% 45.18% 41.38% 50.15% 48.00%
EBITDA Margin		 -91.20% -43.46% -5.35% 3.09% -3.54% 3.95% 4.50% -5.61% -10.85% 11.00% 0.75%
Operating Margin		 -92.26% -44.18% -6.69% 1.00% -5.98% 0.89% 1.24% -9.76% -14.67% 8.00% -1.92%
EBIT Margin		 -92.60% -44.55% -7.13% 0.85% -6.11% 1.06% 1.19% -9.78% -14.57% 8.12% -1.56%
Profit (Net Income) Margin		 -93.41% -44.67% -7.29% 0.47% -6.52% 0.88% 1.12% -9.90% -14.51% 8.26% -1.98%
Tax Burden Percent		 100.88% 100.28% 102.29% 55.41% 106.62% 82.84% 94.00% 101.29% 99.56% 101.62% 126.48%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 44.59% 0.00% 17.16% 6.00% 0.00% 0.00% -1.62% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 40.32% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 40.65% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -33.69% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -251.79% -2,157.99% -732.51% 11.42% -57.05% 5.78% 6.63% -77.70% -532.46% 503.05% -29.97%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -207.25% 227.74% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -116.18% -99.58% -17.94% 2.39% -12.26% 1.81% 1.85% -15.12% -24.18% 15.82% -3.13%
Return on Assets (ROA)		 -117.21% -99.85% -18.35% 1.32% -13.07% 1.50% 1.74% -15.31% -24.08% 16.08% -3.96%
Return on Common Equity (ROCE)		 -251.79% -2,157.99% -732.51% 11.42% -57.05% 5.78% 6.63% -77.70% -532.46% 503.05% -29.48%
Return on Equity Simple (ROE_SIMPLE)		 -4,388.88% -1,721.00% 0.00% 5.72% -41.05% 4.87% 6.02% -115.08% 382.34% 124.63% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.22 -4.77 -0.95 0.15 -1.34 0.30 0.57 -3.68 -5.15 4.63 -0.80
NOPAT Margin		 -64.58% -30.93% -4.68% 0.55% -4.19% 0.74% 1.16% -6.83% -10.27% 8.13% -1.34%
Net Nonoperating Expense Percent (NNEP)		 -52.62% -68.53% -29.74% -1.30% -12.94% 0.90% -0.33% -17.32% -33.40% 1.20% -5.14%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 270.58% 122.66% -19.62%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 52.92% 52.26% 48.12% 54.82% 58.62% 49.85% 52.00%
SG&A Expenses to Revenue		 46.26% 32.20% 20.11% 17.28% 20.59% 15.87% 18.56% 19.01% 22.07% 16.40% 18.77%
R&D to Revenue		 37.51% 27.86% 21.74% 17.73% 18.22% 17.53% 19.09% 21.43% 19.03% 11.99% 15.29%
Operating Expenses to Revenue		 192.26% 144.18% 106.69% 99.00% 53.06% 46.85% 50.64% 54.94% 56.05% 42.15% 49.92%
Earnings before Interest and Taxes (EBIT)		 -10 -6.87 -1.44 0.23 -1.96 0.44 0.58 -5.27 -7.31 4.63 -0.93
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -10 -6.70 -1.08 0.84 -1.14 1.62 2.21 -3.02 -5.44 6.27 0.45
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 140.77 72.73 15,896.96 47.13 18.00 19.34 11.42 14.39 0.00 26.21 21.01
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 67.22 19.26 20.26 11.85 15.51 0.00 28.76 22.96
Price to Revenue (P/Rev)		 3.00 1.89 2.36 3.90 2.86 3.50 2.11 1.24 1.31 1.74 1.39
Price to Earnings (P/E)		 0.00 0.00 0.00 823.96 0.00 396.90 189.51 0.00 0.00 21.03 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.12% 0.00% 0.25% 0.53% 0.00% 0.00% 4.76% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 50.71 1,065.68 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 2.77 1.67 2.36 3.78 2.60 3.39 1.93 1.05 1.26 1.56 1.31
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 122.16 0.00 85.74 42.92 0.00 0.00 14.22 174.16
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 442.62 0.00 318.05 162.69 0.00 0.00 19.26 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 683.41 0.00 458.43 166.23 0.00 0.00 19.25 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 54.91 28.72 0.00 14.60 14.25 0.00 12.06 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 99.40 91.15 0.00 29.43 29.91 0.00 14.56 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 14.33 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 5.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.48 -9.69 -8.81 -1.49 -1.58 -1.04 -0.83 -1.39 -4.66 -6.64 -1.87
Leverage Ratio		 2.15 21.61 39.92 8.63 4.36 3.86 3.81 5.07 22.12 31.29 7.57
Compound Leverage Factor		 2.15 21.61 39.92 8.63 4.36 3.86 3.81 5.07 22.12 31.29 7.57
Debt to Total Capital		 0.00% 0.00% 93.48% 0.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 56.52% 0.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 36.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.17%
Common Equity to Total Capital		 100.00% 100.00% 6.52% 99.29% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 96.83%
Debt to EBITDA		 0.00 0.00 -0.04 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 -0.04 -3.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.05 0.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 -0.05 -21.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -15.69 -10.97 -7.17 0.68 -0.09 2.20 1.04 -0.82 -2.49 0.80 0.02
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.65%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.82 0.79 0.68 0.99 1.10 1.13 1.13 0.90 0.63 0.94 0.96
Quick Ratio		 0.73 0.75 0.53 0.95 1.07 1.04 1.06 0.83 0.56 0.88 0.91
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.19 -4.22 -3.89 1.03 0.92 -5.68 3.22 1.89 -6.11 6.12 -6.01
Operating Cash Flow to CapEx		 -1,990.06% -370.76% -100.00% 223.26% 130.86% -51.23% 272.53% 138.30% -734.09% 1,898.71% -828.15%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.25 2.24 2.52 2.80 2.01 1.70 1.56 1.55 1.66 1.95 2.00
Accounts Receivable Turnover		 9.43 8.60 6.54 6.53 7.02 6.98 5.95 6.15 5.72 5.49 4.87
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 20.90 16.81 12.27 11.69 9.83 0.00 0.00 7.52 7.77 11.28 15.04
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 5.72 8.52 9.93 7.20 5.28 5.65 5.54
Days Sales Outstanding (DSO)		 38.71 42.47 55.82 55.92 51.97 52.28 61.31 59.37 63.81 66.53 74.88
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 63.84 42.84 36.77 50.69 69.11 64.59 65.86
Cash Conversion Cycle (CCC)		 38.71 42.47 55.82 55.92 -11.88 9.44 24.54 8.68 -5.30 1.94 9.02
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.50 -3.05 -0.10 -0.98 -3.24 2.74 0.09 -5.48 -4.52 -6.01 -0.80
Invested Capital Turnover		 -5.65 -5.56 -12.86 -49.80 -15.20 -163.51 34.71 -19.98 -10.03 -10.81 -17.43
Increase / (Decrease) in Invested Capital		 -1.04 -0.55 2.94 -0.88 -2.26 5.98 -2.65 -5.57 0.96 -1.49 5.21
Enterprise Value (EV)		 31 26 48 102 83 139 95 57 63 89 78
Market Capitalization		 34 29 48 105 92 144 104 67 66 99 83
Book Value per Share		 $0.03 $0.04 $0.00 $0.19 $0.43 $0.55 $0.67 $0.34 ($0.14) $0.27 $0.28
Tangible Book Value per Share		 ($0.05) ($0.02) ($0.06) $0.14 $0.40 $0.53 $0.65 $0.32 ($0.16) $0.25 $0.26
Total Capital		 0.24 0.40 0.05 2.25 5.10 7.43 9.10 4.64 -1.90 3.77 4.07
Total Debt		 0.00 0.00 0.04 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -2.59 -3.30 0.04 -3.22 -8.34 -4.69 -9.01 -10 -2.62 -9.79 -4.87
Capital Expenditures (CapEx)		 0.32 0.77 1.23 0.83 2.22 3.28 2.38 2.87 0.84 0.39 0.54
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.55 -4.87 -2.37 -3.32 -7.15 -3.26 -6.82 -12 -11 -11 -5.58
Debt-free Net Working Capital (DFNWC)		 -0.97 -1.58 -2.37 -0.09 1.19 1.43 2.19 -2.28 -7.90 -1.48 -0.70
Net Working Capital (NWC)		 -0.97 -1.58 -2.39 -0.10 1.19 1.43 2.19 -2.28 -7.90 -1.48 -0.70
Net Nonoperating Expense (NNE)		 3.22 2.12 0.53 0.02 0.75 -0.06 0.02 1.66 2.13 -0.07 0.38
Net Nonoperating Obligations (NNO)		 -2.74 -3.45 -0.11 -3.22 -8.34 -4.69 -9.01 -10 -2.62 -9.79 -4.87
Total Depreciation and Amortization (D&A)		 0.16 0.17 0.36 0.61 0.83 1.18 1.63 2.25 1.87 1.64 1.38
Debt-free, Cash-free Net Working Capital to Revenue		 -31.76% -31.62% -11.69% -12.28% -22.26% -7.93% -13.89% -23.01% -20.98% -19.79% -9.38%
Debt-free Net Working Capital to Revenue		 -8.64% -10.24% -11.69% -0.32% 3.71% 3.49% 4.45% -4.23% -15.76% -2.61% -1.18%
Net Working Capital to Revenue		 -8.64% -10.24% -11.82% -0.38% 3.71% 3.49% 4.45% -4.23% -15.76% -2.61% -1.18%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.20) ($0.64) ($0.13) $0.01 ($0.17) $0.03 $0.04 ($0.39) ($0.54) $0.34 ($0.08)
Adjusted Weighted Average Basic Shares Outstanding		 8.70M 10.98M 11.03M 11.34M 11.84M 13.14M 13.20M 13.54M 13.55M 13.66M 13.83M
Adjusted Diluted Earnings per Share		 ($1.20) ($0.64) ($0.13) $0.01 ($0.17) $0.02 $0.04 ($0.39) ($0.54) $0.33 ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding		 8.70M 10.98M 11.03M 14.10M 11.84M 14.57M 14.16M 13.54M 13.55M 14.27M 13.83M
Adjusted Basic & Diluted Earnings per Share		 ($1.20) ($0.64) ($0.13) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 11.24M 10.68M 10.99M 11.62M 12.73T 13.42M 13.52M 13.46M 13.59M 13.78M 13.89M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.22 -4.77 -0.95 0.15 -1.11 0.30 0.57 -3.11 -4.84 3.39 -0.72
Normalized NOPAT Margin		 -64.58% -30.93% -4.68% 0.55% -3.46% 0.74% 1.16% -5.78% -9.66% 5.96% -1.21%
Pre Tax Income Margin		 -92.60% -44.55% -7.13% 0.85% -6.11% 1.06% 1.19% -9.78% -14.57% 8.12% -1.56%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.39% -8.71% 0.00% 0.00%

Quarterly Metrics And Ratios for Champions Oncology

This table displays calculated financial ratios and metrics derived from Champions Oncology's official financial filings.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025 7/31/2025 10/31/2025 1/31/2026 4/30/2026
DEI Shares Outstanding		 13,479,215.00 13,593,767.00 13,593,767.00 13,593,766.00 13,593,767.00 13,819,236.00 13,826,904.00 13,777,170.00 13,788,421.00 13,886,326.00 13,886,826.00
DEI Adjusted Shares Outstanding		 13,479,215.00 13,593,767.00 13,593,767.00 13,593,766.00 13,593,767.00 13,819,236.00 13,826,904.00 13,777,170.00 13,788,421.00 13,886,326.00 13,886,826.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.15 -0.19 -0.01 0.10 0.05 0.33 -0.13 -0.03 0.02 -0.02 -0.05
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -18.96% -5.90% 7.12% 11.94% 16.56% 41.77% -11.76% -0.47% 11.46% - 11.99%
EBITDA Growth		 -382.44% -10.34% 113.59% 185.19% 172.21% 341.22% -690.60% -105.27% -46.22% - 88.92%
EBIT Growth		 -102,900.00% -4.01% 92.48% 152.56% 135.87% 279.36% -928.80% -133.88% -65.49% - 74.81%
NOPAT Growth		 -28,028.57% -4.84% 89.21% 173.22% 152.69% 348.13% -637.87% -128.20% -76.16% - 73.99%
Net Income Growth		 -12,843.75% -3.73% 95.74% 151.17% 135.15% 277.67% -1,583.49% -135.49% -67.45% - 63.65%
EPS Growth		 0.00% -5.56% 94.74% 147.37% 133.33% 263.16% -1,100.00% -133.33% -60.00% - 58.33%
Operating Cash Flow Growth		 -82.08% -158.42% -162.43% 107.79% -148.05% 153.32% 478.19% 92.93% -513.07% - -129.09%
Free Cash Flow Firm Growth		 -51.70% -100.23% -130.25% -30.29% -209.53% -52,658.27% 107.56% 103.96% 190.79% - -6,500.00%
Invested Capital Growth		 -227.69% -39.21% 17.53% -8.70% 61.75% 135.55% -33.00% -110.51% -106.71% - 86.63%
Revenue Q/Q Growth		 -7.87% 3.85% 16.50% 0.42% -4.07% 26.32% -27.49% 13.27% 7.43% - -16.44%
EBITDA Q/Q Growth		 24.70% -29.31% 113.05% 570.30% -36.18% 331.99% -131.96% 94.02% 751.06% - -267.31%
EBIT Q/Q Growth		 18.83% -22.28% 92.42% 798.43% -44.60% 511.37% -143.49% 77.00% 156.42% - -108.86%
NOPAT Q/Q Growth		 23.39% -31.82% 89.45% 787.02% -44.87% 520.73% -131.39% 73.74% 146.61% - -89.13%
Net Income Q/Q Growth		 19.29% -22.16% 95.69% 1,304.59% -44.55% 517.45% -140.82% 74.60% 150.86% - -139.07%
EPS Q/Q Growth		 21.05% -26.67% 94.74% 1,000.00% -44.44% 520.00% -138.71% 75.00% 166.67% - -150.00%
Operating Cash Flow Q/Q Growth		 114.76% -256.03% -97.61% 117.13% -191.00% 273.14% 1,301.63% -91.26% -389.17% - -49.22%
Free Cash Flow Firm Q/Q Growth		 6.72% -100.33% -14,474.68% 236.02% -267.67% -58.72% 102.09% 3,567.16% -25.36% - -215.58%
Invested Capital Q/Q Growth		 -82.74% -17.66% 29.10% 28.69% 35.70% 209.36% -365.24% -12.87% 36.86% - 70.75%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 42.82% 34.70% 48.22% 49.70% 44.93% 61.17% 41.14% 42.87% 51.70% - 50.79%
EBITDA Margin		 -13.62% -16.96% 1.90% 12.68% 8.44% 28.85% -12.72% -0.67% 4.07% - -1.26%
Operating Margin		 -16.89% -21.44% -1.94% 9.45% 5.43% 26.40% -16.24% -3.77% 1.23% - -3.77%
EBIT Margin		 -17.80% -20.96% -1.36% 9.49% 5.48% 26.52% -15.90% -3.23% 1.70% - -3.58%
Profit (Net Income) Margin		 -17.90% -21.05% -0.78% 9.34% 5.40% 26.38% -14.85% -3.33% 1.58% - -4.82%
Tax Burden Percent		 100.53% 100.44% 57.07% 98.43% 98.51% 99.49% 93.38% 103.10% 92.94% - 134.75%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 1.57% 1.49% 0.51% 0.00% 0.00% 7.06% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -208.03% -388.65% -532.46% -432.46% -154.52% 376.84% 503.05% 182.28% 98.98% - -29.97%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -102.76% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 -27.52% -32.78% -2.26% 17.87% 10.96% 54.12% -30.98% -6.62% 3.58% - -7.17%
Return on Assets (ROA)		 -27.66% -32.93% -1.29% 17.59% 10.80% 53.84% -28.93% -6.83% 3.32% - -9.66%
Return on Common Equity (ROCE)		 -208.03% -388.65% -532.46% -432.46% -154.52% 376.84% 503.05% 180.58% 97.75% - -29.48%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 472.69% 0.00% 0.00% 0.00% 117.52% 0.00% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.37 -1.80 -0.19 1.31 0.72 4.48 -1.40 -0.37 0.17 -0.19 -0.37
NOPAT Margin		 -11.82% -15.01% -1.36% 9.30% 5.35% 26.27% -11.37% -2.64% 1.14% - -2.64%
Net Nonoperating Expense Percent (NNEP)		 -8.60% -9.10% 1.28% 0.13% 0.17% 0.50% -6.94% -1.47% 1.15% - -4.12%
Return On Investment Capital (ROIC_SIMPLE)		 -1,471.51% 87.65% 10.01% -394.00% 105.89% 81.84% -37.25% -10.43% 4.06% -4.41% -8.98%
Cost of Revenue to Revenue		 57.18% 65.30% 51.78% 50.30% 55.07% 38.83% 58.86% 57.13% 48.30% - 49.21%
SG&A Expenses to Revenue		 22.47% 23.00% 19.73% 17.97% 14.00% 14.07% 20.44% 18.36% 19.78% - 19.03%
R&D to Revenue		 21.73% 18.19% 14.64% 10.34% 12.52% 10.09% 15.89% 14.88% 17.40% - 15.29%
Operating Expenses to Revenue		 59.71% 56.14% 50.16% 40.25% 39.51% 34.76% 57.39% 46.64% 50.47% - 54.56%
Earnings before Interest and Taxes (EBIT)		 -2.06 -2.52 -0.19 1.33 0.74 4.52 -1.97 -0.45 0.26 -0.24 -0.50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.58 -2.04 0.27 1.78 1.14 4.92 -1.57 -0.09 0.61 0.10 -0.17
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 791.36 0.00 0.00 0.00 78.05 27.77 26.21 24.82 22.62 - 21.01
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 153.62 29.58 28.76 27.44 24.59 - 22.96
Price to Revenue (P/Rev)		 1.47 1.60 1.31 1.26 0.99 2.59 1.74 1.53 1.61 - 1.39
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 23.63 21.03 29.50 37.85 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 4.23% 4.76% 3.39% 2.64% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 65.58 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 1.36 1.51 1.26 1.20 0.94 2.54 1.56 1.35 1.47 - 1.31
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 43.86 18.35 14.22 17.49 22.23 - 174.16
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 23.23 19.26 27.03 36.44 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 23.54 19.25 27.67 38.70 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 12.06 10.00 13.80 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 14.56 12.11 19.38 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -1.76 -3.19 -4.66 -4.94 -10.68 -2.20 -6.64 -4.12 -2.29 - -1.87
Leverage Ratio		 6.98 12.57 22.12 34.91 69.17 16.83 31.29 17.30 11.28 - 7.57
Compound Leverage Factor		 6.98 12.57 22.12 34.91 69.17 16.83 31.29 17.30 11.28 - 7.57
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.85% 1.44% - 3.17%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.15% 98.56% - 96.83%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 -1.26 -1.64 -1.59 -1.17 -1.29 2.45 0.12 0.00 0.40 - 0.07
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.94% 1.24% - 1.65%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.67 0.60 0.63 0.69 0.75 0.99 0.94 0.93 0.96 - 0.96
Quick Ratio		 0.63 0.56 0.56 0.62 0.70 0.96 0.88 0.87 0.91 - 0.91
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 2.40 -0.01 -1.15 1.57 -2.63 -4.17 0.09 3.19 2.38 4.82 -5.57
Operating Cash Flow to CapEx		 745.57% -998.91% 0.00% 0.00% -301.06% 1,166.67% 2,714.62% 1,304.35% -716.94% - -839.50%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.55 1.56 1.66 1.88 2.00 2.04 1.95 2.05 2.11 - 2.00
Accounts Receivable Turnover		 6.00 6.17 5.72 5.75 5.89 4.95 5.49 6.15 5.31 - 4.87
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 6.82 6.84 7.77 8.17 9.00 10.13 11.28 11.97 13.10 - 15.04
Accounts Payable Turnover		 6.42 6.51 5.28 5.24 6.30 5.76 5.65 5.82 5.37 - 5.54
Days Sales Outstanding (DSO)		 60.88 59.13 63.81 63.52 61.98 73.75 66.53 59.38 68.75 - 74.88
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 56.86 56.03 69.11 69.69 57.90 63.36 64.59 62.76 67.92 - 65.86
Cash Conversion Cycle (CCC)		 4.02 3.09 -5.30 -6.17 4.09 10.39 1.94 -3.38 0.83 - 9.02
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -5.42 -6.38 -4.52 -3.22 -2.07 2.27 -6.01 -6.79 -4.29 -2.75 -0.80
Invested Capital Turnover		 -14.13 -8.98 -10.03 -16.69 -14.30 -28.51 -10.81 -11.36 -18.38 - -17.43
Increase / (Decrease) in Invested Capital		 -3.77 -1.80 0.96 -0.26 3.35 8.64 -1.49 -3.56 -2.21 -5.02 5.21
Enterprise Value (EV)		 68 75 63 62 50 149 89 77 86 - 78
Market Capitalization		 74 79 66 65 53 152 99 87 94 - 83
Book Value per Share		 $0.01 ($0.15) ($0.14) ($0.02) $0.05 $0.40 $0.27 $0.25 $0.30 $0.31 $0.28
Tangible Book Value per Share		 ($0.02) ($0.18) ($0.16) ($0.05) $0.03 $0.37 $0.25 $0.23 $0.28 $0.28 $0.26
Total Capital		 0.09 -2.06 -1.90 -0.33 0.68 5.47 3.77 3.54 4.23 4.38 4.07
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -5.51 -4.47 -2.62 -2.89 -2.75 -3.20 -9.79 -10 -8.52 -7.13 -4.87
Capital Expenditures (CapEx)		 0.08 0.09 -0.00 0.00 0.09 0.04 0.25 0.05 0.24 0.04 0.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -13 -11 -8.88 -7.53 -3.38 -11 -12 -9.33 -7.62 -5.58
Debt-free Net Working Capital (DFNWC)		 -6.93 -8.77 -7.90 -5.99 -4.78 -0.17 -1.48 -1.68 -0.81 -0.49 -0.70
Net Working Capital (NWC)		 -6.93 -8.77 -7.90 -5.99 -4.78 -0.17 -1.48 -1.68 -0.81 -0.49 -0.70
Net Nonoperating Expense (NNE)		 0.70 0.73 -0.08 -0.00 -0.01 -0.02 0.43 0.10 -0.07 0.09 0.30
Net Nonoperating Obligations (NNO)		 -5.51 -4.32 -2.62 -2.89 -2.75 -3.20 -9.79 -10 -8.52 -7.13 -4.87
Total Depreciation and Amortization (D&A)		 0.48 0.48 0.46 0.45 0.40 0.40 0.39 0.36 0.36 0.34 0.32
Debt-free, Cash-free Net Working Capital to Revenue		 -24.90% -26.90% -20.98% -17.19% -14.06% -5.76% -19.79% -21.11% -15.96% - -9.38%
Debt-free Net Working Capital to Revenue		 -13.87% -17.82% -15.76% -11.59% -8.92% -0.30% -2.61% -2.96% -1.38% - -1.18%
Net Working Capital to Revenue		 -13.87% -17.82% -15.76% -11.59% -8.92% -0.30% -2.61% -2.96% -1.38% - -1.18%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.15) ($0.19) ($0.01) $0.10 $0.05 $0.33 ($0.14) ($0.03) $0.02 ($0.02) ($0.05)
Adjusted Weighted Average Basic Shares Outstanding		 13.50M 13.59M 13.55M 13.59M 13.59M 13.70M 13.66M 13.79M 13.79M 13.89M 13.83M
Adjusted Diluted Earnings per Share		 ($0.15) ($0.19) ($0.01) $0.09 $0.05 $0.31 ($0.12) ($0.03) $0.02 ($0.02) ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding		 13.50M 13.59M 13.55M 14.04M 14.02M 14.36M 14.27M 13.79M 14.46M 13.89M 13.83M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 13.59M 13.59M 13.59M 13.59M 13.82M 13.83M 13.78M 13.79M 13.89M 13.89M 13.89M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.37 -1.80 -0.19 1.31 0.72 4.48 -1.40 -0.35 0.17 -0.13 -0.36
Normalized NOPAT Margin		 -11.82% -15.01% -1.36% 9.30% 5.35% 26.27% -11.37% -2.54% 1.14% - -2.63%
Pre Tax Income Margin		 -17.80% -20.96% -1.36% 9.49% 5.48% 26.52% -15.90% -3.23% 1.70% - -3.58%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 -7.35% -7.28% -8.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Champions Oncology’s recent results show improving profitability versus the prior year, but a sharp deterioration in operating cash flow and liquidity during fiscal 2026. Revenue reached $13.8 million in Q4 2026, up from $12.4 million in Q4 2025, while the company’s net loss narrowed to $667,000 from $1.8 million. However, revenue declined sequentially from $16.6 million in Q3, and the company has reported operating cash outflows in three of the last four quarters.

  • Year-over-year revenue growth: Q4 2026 revenue increased approximately 12% from Q4 2025. Revenue also improved from $12.0 million in Q3 2024 to $13.8 million in the latest quarter, although quarterly results remain volatile.
  • Gross margin improved substantially: Q4 2026 gross profit was $7.0 million, representing a gross margin of approximately 50.8%, compared with 41.1% in Q4 2025 and 34.7% in Q3 2024.
  • Losses narrowed from the prior year: The Q4 2026 net loss attributable to common shareholders was $728,000, or $0.05 per share, versus a $1.8 million loss, or $0.14 per share, in Q4 2025.
  • Operating losses have generally improved from fiscal 2025: The latest operating loss of $522,000 was significantly better than the $2.0 million operating loss reported in Q4 2025. Champions Oncology also generated operating income in Q2 2026, although that improvement was not sustained.
  • Balance-sheet equity has recovered: Total equity and noncontrolling interests increased to $4.4 million at January 31, 2026, from negative $332,000 at July 31, 2024. This provides a stronger capital position than the company had earlier in the period.
  • Research and development spending remains significant: Q4 2026 research and development expense was $2.1 million, while marketing expense was $2.8 million. These investments may support future growth, but they also consume resources while the company remains unprofitable.
  • Accounts receivable is a major working-capital asset: Accounts receivable rose from $9.5 million in Q1 2026 to $12.1 million in Q3. Strong collections could support future cash flow, but the increase also helps explain the company’s heavy cash usage.
  • Operating cash flow turned sharply negative: Cash flow from operations was negative $1.7 million in Q2 2026, negative $1.3 million in Q3 and negative $2.0 million in Q4. The latest outflow was driven primarily by a $2.0 million use of cash from operating assets and liabilities.
  • Cash reserves are declining: Cash fell from $10.3 million at July 31, 2025, to $8.5 million at October 31 and $7.1 million at January 31, 2026. If the Q4 cash-flow figures are applied to the Q3 balance, ending cash would be approximately $4.9 million before any other balance-sheet changes.
  • Liquidity is becoming tight: At January 31, 2026, current assets of $20.2 million were slightly below current liabilities of $20.7 million, producing a current ratio of roughly 0.98. The company also continues to carry substantial deferred revenue and other operating liabilities.

Overall, the income statement is moving in a better direction compared with fiscal 2025: gross margins are stronger, revenue is higher year over year and losses are smaller. Nevertheless, the sequential revenue decline in Q4 2026 and persistent operating cash burn are important risks. Investors should monitor whether Champions Oncology can convert its revenue and accounts receivable into cash while returning to consistent operating profitability.

08/16/26 10:55 AM ETAI Generated. May Contain Errors.

Champions Oncology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Champions Oncology's financial year ends in April. Their financial year 2026 ended on April 30, 2026.

Champions Oncology's net income appears to be on a downward trend, with a most recent value of -$1.18 million in 2026, falling from -$10.45 million in 2016. The previous period was $4.70 million in 2025. Find out what analysts predict for Champions Oncology in the coming months.

Champions Oncology's total operating income in 2026 was -$1.14 million, based on the following breakdown:
  • Total Gross Profit: $28.53 million
  • Total Operating Expenses: $29.67 million

Over the last 10 years, Champions Oncology's total revenue changed from $11.18 million in 2016 to $59.43 million in 2026, a change of 431.4%.

Champions Oncology's total liabilities were at $22.92 million at the end of 2026, a 19.8% decrease from 2025, and a 313.8% increase since 2016.

In the past 10 years, Champions Oncology's cash and equivalents has ranged from $0.00 in 2018 to $10.12 million in 2023, and is currently $4.87 million as of their latest financial filing in 2026.

Over the last 10 years, Champions Oncology's book value per share changed from 0.03 in 2016 to 0.28 in 2026, a change of 939.2%.


Related Companies

Financial statements for NASDAQ:CSBR last updated on 7/27/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
A Dark Day Is Coming to America
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
SpaceX pays a 10X launch penalty
SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...
Freedom Financial | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel